Banner
targets (2)
for drugs
Identification
Name Aluminium
Accession Number DB01370
Type small molecule
Groups approved
Description

A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98. [PubChem]
Structure Thumb
Download: MOL | SDF | SMILES | InChI
Display: 2D Structure | 3D Structure
Synonyms Not Available
Salts Not Available
Brand names Not Available
Brand mixtures Not Available
Categories Not Available
CAS number 7429-90-5
Weight Average: 26.9815386
Monoisotopic: 26.981538441
Chemical Formula Al
InChI Key InChIKey=XAGFODPZIPBFFR-UHFFFAOYSA-N
InChI
InChI=1S/Al
Plain Text
IUPAC Name
alumane
SMILES
[Al]
Plain Text
Mass Spec Not Available
Taxonomy
Kingdom Inorganic
Classes
  • Inorganic Ions and Gases
Substructures
  • Inorganic Ions and Gases
Pharmacology
Indication Not Available
Pharmacodynamics Not Available
Mechanism of action Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot.
Absorption Not Available
Volume of distribution Not Available
Protein binding Not Available
Metabolism Not Available
Route of elimination Not Available
Half life Not Available
Clearance Not Available
Toxicity Not Available
Affected organisms Not Available
Pathways Not Available
Pharmacoeconomics
Manufacturers Not Available
Packagers Not Available
Dosage forms
Form Route Strength
Aerosol Oral
Aerosol Topical
Capsule Oral
Cream Topical
Emulsion Topical
Gel Dental
Gel Topical
Liquid Dental
Liquid Oral
Liquid Sublingual
Liquid Topical
Lotion Topical
Paste Oral
Powder Oral
Powder Topical
Solution Topical
Solution / drops Oral
Spray Topical
Stick Topical
Suspension Oral
Suspension Topical
Tablet Oral
First Prev Next Last
Prices Not Available
Patents Not Available
Properties
State solid
Experimental Properties
Property Value Source
melting point 2.375 g·cm −3 Not Available
Predicted Properties
Property Value Source
logP 1.45 ChemAxon
physiological charge 0 ChemAxon
hydrogen acceptor count 0 ChemAxon
hydrogen donor count 0 ChemAxon
polar surface area 0 ChemAxon
rotatable bond count 0 ChemAxon
refractivity 0 ChemAxon
polarizability 1.78 ChemAxon
References
Synthesis Reference Not Available
General Reference Not Available
External Links
Resource Link
KEGG Compound C06264 Link_out
PubChem Compound 5359268 Link_out
PubChem Substance 46504765 Link_out
ChemSpider 4514248 Link_out
ChEBI 28984 Link_out
ChEMBL 28984 Link_out
Therapeutic Targets Database DAP000467 Link_out
PharmGKB PA164760864 Link_out
Drug Product Database 13838 Link_out
Wikipedia http://en.wikipedia.org/wiki/Aluminium Link_out
ATC Codes
  • A02AB07
  • A02AB03
  • C10AB03
  • D10AX01
  • C10AD04
  • C05AX01
  • A01AD11
  • A02AB01
  • M05BX02
  • D09AA08
  • D10AX04
  • A02AB05
  • S02AA04
AHFS Codes
  • 88:29.00*
  • 34:00.00
  • 56:04.00
  • 52:28.00
  • 84:12.00
  • 92:02.00*
  • 84:92.00
  • 84:04.92
  • 20:12.12
PDB Entries Not Available
FDA label Not Available
MSDS Not Available
Interactions
Drug Interactions
Drug Interaction
Amprenavir The antiacid decreases the absorption of amprenavir
Atazanavir This gastric pH modifier decreases the levels/effects of atazanavir
Chloroquine The antiacid decreases the absorption of chloroquine
Ciprofloxacin Formation of non-absorbable complexes
Clindamycin The aluminium salt decreases the absorption of lincosamides
Clodronate Formation of non-absorbable complexes
Dapsone Formation of non-absorbable complexes
Deferasirox Possible physicochemical interaction
Delavirdine The antiacid decreases the effect of delavirdine
Demeclocycline Formation of non-absorbable complexes
Doxycycline Formation of non-absorbable complexes
Etidronic acid Formation of non-absorbable complexes
Fosamprenavir The antiacid decreases the absorption of amprenavir
Gatifloxacin Formation of non-absorbable complexes
Gemifloxacin Formation of non-absorbable complexes
Grepafloxacin Formation of non-absorbable complexes
Ibandronate Formation of non absorbable complexes
Indinavir The antacid decreases the absorption of indinavir
Itraconazole Aluminum-containing antacids may decrease the effect of itraconazole.
Ketoconazole Aluminum-containing antacids may decrease the effect of ketoconazole.
Levofloxacin Formation of non-absorbable complexes
Lincomycin The aluminium salt decreases the absorption of lincosamides
Minocycline Formation of non-absorbable complexes
Moxifloxacin Formation of non-absorbable complexes
Norfloxacin Formation of non-absorbable complexes
Ofloxacin Formation of non-absorbable complexes
Penciclovir The multivalent agent decreases the effect of penicillamine
Polystyrene sulfonate Risk of alkalosis in renal impairment
Tetracycline Formation of non-absorbable complexes
Trovafloxacin Aluminum may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the aluminum containing agent to minimize the interaction.
Food Interactions Not Available
Targets

1. Serotransferrin

Pharmacological action: unknown

Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation

Organism class: human
UniProt ID: P02787 Link_out
Gene: TF Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Nolte E, Beck E, Winklhofer C, Steinhausen C: Compartmental model for aluminium biokinetics. Hum Exp Toxicol. 2001 Feb;20(2):111-7. Pubmed
  2. Nagaoka MH, Maitani T: Binding affinity of aluminium to human serum transferrin and effects of carbohydrate chain modification as studied by HPLC/high-resolution ICP-MS—speciation of aluminium in human serum. J Inorg Biochem. 2005 Sep;99(9):1887-94. Pubmed
  3. Mizutani K, Mikami B, Aibara S, Hirose M: Structure of aluminium-bound ovotransferrin at 2.15 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1636-42. Epub 2005 Nov 19. Pubmed
  4. Beardmore J, Rugg G, Exley C: A systems biology approach to the blood-aluminium problem: The application and testing of a computational model. J Inorg Biochem. 2007 Sep;101(9):1187-91. Epub 2007 Jun 12. Pubmed

2. Sodium/potassium-transporting ATPase alpha-1 chain

Pharmacological action: unknown
Actions: binder

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients

Organism class: human
UniProt ID: P05023 Link_out
Gene: ATP1A1 Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Menz RI, Walker JE, Leslie AG: Structure of bovine mitochondrial F(1)-ATPase with nucleotide bound to all three catalytic sites: implications for the mechanism of rotary catalysis. Cell. 2001 Aug 10;106(3):331-41. Pubmed
  2. Silva VS, Goncalves PP: The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. Pubmed
  3. Amador FC, Santos MS, Oliveira CR: Lipid peroxidation and aluminium effects on the cholinergic system in nerve terminals. Neurotox Res. 2001 Jul;3(3):223-33. Pubmed
  4. Kohila T, Parkkonen E, Tahti H: Evaluation of the effects of aluminium, ethanol and their combination on rat brain synaptosomal integral proteins in vitro and after 90-day oral exposure. Arch Toxicol. 2004 May;78(5):276-82. Pubmed
  5. Kohila T, Tahti H: Effects of aluminium and lead on ATPase activity of knockout +/- mouse cerebral synaptosomes in vitro. Altern Lab Anim. 2004 Oct;32(4):361-7. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
Comments
Drug created on July 06, 2007 14:27 / Updated on February 08, 2013 16:20